Investigation of the prognostic value of the apoptotic marker p53 gene and vascular endothelial growth factor in evaluating the clinical course of nasopharyngeal angiofibroma
https://doi.org/10.17650/2222-1468-2015-5-2-25-29
Abstract
Objective. To investigate the prognostic value of the apoptotic markers (p53) and vascular endothelial growth factor (VEGF) in evaluating the clinical course of juvenile nasopharyngeal angiofibroma (JNA).
Subjects and methods. The investigation enrolled 43 patients with primary JNA (a study group) and 20 with its relapses (a control group). The expression of VEGF and mutant p53 (mtp53) gene was immunohistochemically determined using DAKO kits (Denmark). The results of reactions with antibodies to VEGF-A and mtp53 located in the nuclei and membranes were expressed as percentages in terms of stained cell counts per 100 cells examined in different visual fields.
Results. An associative analysis showed that both study and control group patients with high mtp53 gene expression in the tumor cells had clinical stages IIIA–B and IV and those in whom the expression of this gene in the tumor cells was weak or absent were found to have clinical stages I and II. The high (3+) and moderate (2+) mtp53 gene expressions suggest that the disease is severe. Consequently, this is of prognostic value and a poor predictor and the absence of mutations or the decreased expression of this gene is associated with a favorable disease outcome.
Our investigations indicated that the high expression of the VEGF gene was detected in none of the tumor specimens. In the study group, the tumor cell expression of this gene was found to be moderate (2+) in 18 (41.9 %) patients, weak in 6 (13.9 %) and absent in 19 (44.2 %) of the 43 patients. In the control group, the absence of VEGF gene expression in the tumor specimens was 9 times lower than that in the study group.
A comparison with the clinical characteristics of the patients demonstrated that in both the study and control groups, the VEGF expression was observed to be moderate, or weak and absent in those with clinical stages IIIA–B and IV or in those with stage II and I, respectively.
Conclusion. The associative analysis showed that both study and control group patients with high tumor cell mtp53 expression had clinical stages IIIA–B and IV.
About the Author
O. B. Abdurakhmanov
Tashkent Institute for Postgraduate Training of Physicians
Russian Federation
51 Parkent St., Tashkent, 100007, Republic of Uzbekistan
Russian Federation
51 Parkent St., Tashkent, 100007, Republic of Uzbekistan
References
1. Арифов С.С., Лутфуллаев У.Л., Лутфуллаев Г.У. Оценка эффективности лечения больных с юношеской ангиофибромой носовой части глотки при кровотечении. Журнал вушних, носових i горлових хвороб 2009;6:85–7. [Arifov S.S., Lutfullayev U.L., Lutfullayev G.U. Assessment of treatment of patients with the juvenile angiofibroma of the nasal part of the pharynx with bleeding. Journal of Otorhinolaryngologic Diseases 2009;6:85–7. (In Russ.)].
2. Герштейн Е.С., Щербаков А.М., Обушева М.Н., Кушлинский Н.Е. Иммуноферментное исследование содержания фактора роста эндотелия сосудов (VEGF) в опухолях и сыворотке крови больных раком молочной железы. Кремлевская медицина 2005;3:45–52. [Herstein E.S., Shcherbakov A.M., Obusheva M.N., Kushlinskiy N.E. Enzyme immunoassay of the content of vascular endothelial growth factor (VEGF) in Tumors and blood serum of breast cancer patients. Kremlyevskaya meditsyna = Kremlin Medicine 2005;3:45–52. (In Russ.)].
3. Киселев С.М., Луценко С.В., Северин С.Е., Северин Е.С. Ингибиторы опухолевого ангиогенеза. Биохимия 2003;68(5):611–31. [Kiselyov S.M., Lutsenko S.V., Severin S.E., Severin E.S. Tumor angiogenesis inhibitors. Biokhimiya = Biochemistry 2003;68(5):611–31. (In Russ.)].
4. Schick B., Rippel C., Brunner C. et al. Numerical sex chromosome aberrations in juvenile angiofibromas: genetic evidence for an androgen-dependent tumor? Oncol Rep 2003;10(5):1251–5.
5. Som M.L., Neffson A.H. Fibromas of the nasopharynx: juvenile and cellular types. Ann Otol Rhinol Laryngol 1940;49(1):211–9.
6. Герштейн Е.С., Щербаков А.М., Алиева С.К. и др. Фактор роста эндотелия сосудов в опухолях и сыворотке крови больных раком молочной железы. Бюллетень экспериментальной биологии 2003;135(1):99–102. [Herstein E.S., Shcherbakov A.M., Aliyeva S.K. et al. Vascular Endothelial Growth Factor in Tumors and Blood Serum of Breast Cancer Patients. Bulleten, eksperimentalnoy biologii = Biological Expert Bulletin 2003;135(1): 99–102. (In Russ.)].
7. Давиденко И.С., Пефти Е.Б., Фокин А.Н. Значение ангиогенеза в терапии метастатического рака молочной железы. Российский биотерапевтический журнал 2007;4:8–12. [Davydenko I.S., Pefti E.B., Fokin A.N. Importance of angiogenesis in therapy of metastatic breast cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Biotherapeutic Journal 2007;4:8–12. (In Russ.)].
8. Карамышева А.Ф. Ангиогенез опухоли: механизмы, новые подходы к терапии. В кн.: Канцерогенез. Под ред. Д.Г. Заридзе. М.: Научный мир, 2000. С. 298–309. [Karamysheva A.F. Tumor angiogenesis: mechanisms, new approaches to therapy: In book: Carcinogenesis. Under the editorship of D.G. Zaridze. Moscow: Nauchnyi mir = Scientific World, 2000. Pp. 298–309. (In Russ.)].
9. Имянитов Е.Н., Моисеенко В.М. Применение молекулярно-генетического анализа для выбора противоопухолевой терапии. Вопросы онкологии 2008; 54(2):121–32. [Imyanitov E.N., Moiseyenko V.M. Application of the molecular genetic analysis for selection of the anti-tumor therapy. Voprosy onkoligii = Oncology Issues 2008;54 (2):121–32. (In Russ.)].
10. Луценко С.В., Киселев С.М., Фельдман Н.Б., Северин С.Е. Молекулярные механизмы ангиогенеза в физиологических и патологических процессах. В кн.: Введение в молекулярную медицину. Под ред. М.А. Пальцева. М.: Медицина, 2004. С. 446–95. [Lutsenko S.V., Kiselyov S.M., Feldman N.B., Severin S.E. Molecular mechanisms of angiogenesis in physiological and pathological processes: In book: Introduction into molecular medicine. Under the editorship of М.А. Paltsev. Moscow: Medicinа, 2004. Pp. 446–95. (In Russ.)].
11. Имянитов Е.Н., Хансон К.П. Молекулярная онкология: клинические аспекты. СПб.: СПбМАПО, 2007. 211 с. [Imyanitov E.N., Hanson K.P. Molecular oncology: clinical aspects. St. Petersburg: SPbMAPO, 2007. 211 p. (In Russ.)].
12. Лукьянова Н.Ю., Кулик Г.И., Чехун В.Ф. Роль генов р53 и bcl-2 в апоптозе и лекарственной резистентности опухолей. Вопросы онкологии 2000;46(2):121–8. [Lukiyanova N.Yu., Kulik G.I., Chekhun V.F. The role of the р53 and bcl-2 genes in the apoptosis and drug resistance of tumors. Voprosy onkologii = Oncology Issues 2000;46(2):121–8. (In Russ.)].
13. Полушкина И.Н., Степанова Е.Б., Дбар Ж.Н. Молекулярно-биологические маркеры, характеризующие апоптоз, пролиферацию и ангиогенез при раке яичников. Вестник РОНЦ им. Н.Н. Блохина РАМН 2004;4:60–4. [Polushkina I.N., Stepanova E.B., Dbar Zh.N. Molecular and biological markers that characterize apoptosis, proliferation, and angiogenesis in ovarian cancer. Vestnik RONC im. N.N. Blokhina RAMN = N.N. Blokhin Russian Cancer Research Center with the RAMS Herald 2004;4:60–4. (In Russ.)].
14. Brentani M.M., Butugan O., Oshima C.T. et al. Multiple steroid receptors in asopharyngeal angiofibromas. Laryngoscope 1989;99(4):398–401.
15. Langerød A., Zhao H., Borgan Ø. et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007;9(3):R30.
16. Пальцева Е.М., Секачева М.И., Федоров Д.Н., Скипенко О.Г. Влияние предоперационной химиотерапии на экспрессию факторов апоптоза в метастазах колоректального рака в печени. Архив патологии 2014;76(4):18–23. [Paltseva E.M., Sekachyova M.I., Fyodorov D.N., Skipenko O.G. Effect of pre-surgery chemotherapy on expression of apoptotic factors in metastases of colorectal cancer in the liver. Arkhiv patologii = Pathology Archive 2014;76(4):18–23. (In Russ.)].
17. Петров С.В., Райхлин Н.Т. Руководство по иммуногистохимической диагностике опухолей человека. Казань: Титул, 2004. 451 с. [Petrov S.V., Reichlin N.T. Manual for immune histochemical diagnosis of human tumors. Kazan: Titul, 2004. 451 p. (In Russ.)].
18. Bouchet B.P., Caron de Fromentel C., Puisieux A., Galmarini C.M. p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006;58(3):190–207.
19. Farag M.M., Ghanimah S.E., Ragaie A., Saleem T.H. Hormonal receptors in juvenile nasopharyngeal angiofibroma. Laryngoscope 1987;97(2):208–11.
20. Karthikeya P., Mahima V.G., Bagewadi S.B. Juvenile nasopharyngeal angiofibroma. Indian J Cancer. Dent Res 2005;16(1):22–6.
21. Пальцев М.А. Введение в молекулярную медицину. М.: Медицина, 2004. 496 с. [Paltsev M.A. Introduction into molecular medicine. Moscow: Medicinа, 2004. 496 p. (In Russ.)].
Review
For citations:
Abdurakhmanov O.B. Investigation of the prognostic value of the apoptotic marker p53 gene and vascular endothelial growth factor in evaluating the clinical course of nasopharyngeal angiofibroma. Head and Neck Tumors (HNT). 2015;5(2):25-29. (In Russ.) https://doi.org/10.17650/2222-1468-2015-5-2-25-29
Views:
1014
Email this article 